<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543813</url>
  </required_header>
  <id_info>
    <org_study_id>CTMX-M-2029-001</org_study_id>
    <nct_id>NCT03543813</nct_id>
  </id_info>
  <brief_title>PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL</brief_title>
  <official_title>A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytomX Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytomX Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human study of CX-2029 is to characterize the safety,&#xD;
      tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029&#xD;
      in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse&#xD;
      large B-cell lymphoma (DLBCL). The antitumor activity of CX-2029 will be evaluated in&#xD;
      subjects with head and neck squamous cell carcinoma (HNSCC), DLBCL, non-small cell lung&#xD;
      cancer (NSCLC) (squamous cell histology only), or esophageal (esophageal adenocarcinoma&#xD;
      [EAC], esophageal squamous cell carcinoma [ESCC], or gastroesophageal [GE] junction) cancer.&#xD;
&#xD;
      PROCLAIM: PRObody CLinical Assessment In Man CX-2029 clinical trial 001&#xD;
&#xD;
      PROBODY is a trademark of CytomX Therapeutics, Inc&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase 1-2, first-in-human study for CX-2029 in subjects with&#xD;
      metastatic or locally advanced unresectable solid tumors or Diffuse large B-cell lymphoma&#xD;
      (DLBCL) without approved life-prolonging treatment options for their malignancy.&#xD;
&#xD;
      The study is divided into 3 parts (arms), as follows:&#xD;
&#xD;
        -  Part A: Dose escalation and determination of the Maximum tolerated dose (MTD) and/or&#xD;
           Recommended Phase 2 dose (RP2D)&#xD;
&#xD;
        -  Part B: Characterization of CX-2029 in the Tumor microenvironment (TME) in subjects with&#xD;
           select tumor types using previously cleared dose levels from Part A&#xD;
&#xD;
        -  Part C: Expansions in select tumor types at the MTD/RP2D as established in Part A&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-2029 as a monotherapy</measure>
    <time_frame>21 days (dose-limiting toxicity period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects experiencing anti-cancer activity (ORR) at various dose levels when given CX-2029 as a monotherapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>CX-2029 Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and Determination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-2029 Biomarker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-2029 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluate antitumor activity of CX-2029</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-2029</intervention_name>
    <description>CX-2029 Monotherapy</description>
    <arm_group_label>CX-2029 Biomarker</arm_group_label>
    <arm_group_label>CX-2029 Escalation</arm_group_label>
    <arm_group_label>CX-2029 Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced&#xD;
             unresectable tumors&#xD;
&#xD;
          2. Patients demonstrating disease progression after treatment with approved therapies&#xD;
             that are known to confer life-prolonging benefit, or who are intolerant to or have&#xD;
             declined treatment&#xD;
&#xD;
          3. Agreement to provide mandatory archival tissue or fresh biopsy&#xD;
&#xD;
          4. At least 18 years of age&#xD;
&#xD;
          5. For Arm A, histologically or cytologically confirmed metastatic or locally advanced&#xD;
             unresectable solid tumor&#xD;
&#xD;
          6. For Arms B and C, histologically or cytologically confirmed metastatic or locally&#xD;
             advanced unresectable HNSCC, DLBCL, NSCLC (squamous cell histology only), or&#xD;
             esophageal (EAC, ESCC, or GE junction) cancer&#xD;
&#xD;
          7. Additional inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neuropathy &gt; Grade 1&#xD;
&#xD;
          2. Serious concurrent illness, including clinically relevant active infection&#xD;
&#xD;
          3. Clinically significant iron metabolism disorders (eg, sickle cell anemia)&#xD;
&#xD;
          4. Significant cardiac disease such as recent myocardial infarction&#xD;
&#xD;
          5. History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome&#xD;
             (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last&#xD;
             6 months, or alcoholic liver disease;&#xD;
&#xD;
          6. Non-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the&#xD;
             underlying neoplasm;&#xD;
&#xD;
          7. History of severe allergic or anaphylactic reactions to previous monoclonal antibody&#xD;
             therapy;&#xD;
&#xD;
          8. Currently receiving anticoagulation therapy with warfarin;&#xD;
&#xD;
          9. Major surgery (requiring general anesthesia) within 3 months prior to dosing.&#xD;
&#xD;
         10. Hepatic impairment which is moderate (Child-Pugh B) or severe (Child-Pugh C)&#xD;
&#xD;
         11. Transfusion dependent anemia with transfusion dependency of â‰¥3 months&#xD;
&#xD;
         12. Use of iron chelators&#xD;
&#xD;
         13. Additional exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Hannah, MD</last_name>
    <role>Study Director</role>
    <affiliation>CytomX Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fred Kerwood</last_name>
    <phone>650-515-3185</phone>
    <email>clinicaltrials@cytomx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research and Excellence</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forrest General Cancer Center</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University - St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University (NYU) Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz, Servicio de OncologÃ­a</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal, START Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Withington</city>
        <state>Manchester Greater</state>
        <zip>M204BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson, West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>solid tumor</keyword>
  <keyword>DLBCL</keyword>
  <keyword>CX-2029</keyword>
  <keyword>PROBODYâ„¢ Therapeutic</keyword>
  <keyword>Drug Conjugate</keyword>
  <keyword>Antibody drug conjugate</keyword>
  <keyword>CD71</keyword>
  <keyword>Transferrin receptor 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

